These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. On the significance of marginally low von Willebrand factor. Onundarson PT; Gudmundsdottir BR; Marder VJ Thromb Haemost; 2008 Dec; 100(6):1213-4. PubMed ID: 19132256 [No Abstract] [Full Text] [Related]
43. The role of molecular genetics in diagnosing von Willebrand disease. James P; Lillicrap D Semin Thromb Hemost; 2008 Sep; 34(6):502-8. PubMed ID: 19085649 [TBL] [Abstract][Full Text] [Related]
44. Acquired von Willebrand syndrome as side effect of valproic acid therapy in children is rare. Eberl W; Budde U; Bentele K; Christen HJ; Knapp R; Mey A; Schneppenheim R Hamostaseologie; 2009 May; 29(2):137-42. PubMed ID: 19404518 [TBL] [Abstract][Full Text] [Related]
47. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. James AH; Kouides PA; Abdul-Kadir R; Edlund M; Federici AB; Halimeh S; Kamphuisen PW; Konkle BA; Martínez-Perez O; McLintock C; Peyvandi F; Winikoff R Am J Obstet Gynecol; 2009 Jul; 201(1):12.e1-8. PubMed ID: 19481722 [TBL] [Abstract][Full Text] [Related]
48. Value assignment of the WHO 2nd International Standard von Willebrand factor, concentrate (09/182). Hubbard AR; Hamill M; Beeharry M; Bevan SA; Heath AB; J Thromb Haemost; 2011 Aug; 9(8):1638-40. PubMed ID: 21831097 [No Abstract] [Full Text] [Related]
49. A rapid and sensitive method for the analysis of von Willebrand factor multimeric structure. Perutelli P; Boeri E; Mori PG Haematologica; 1997; 82(4):510. PubMed ID: 9299878 [No Abstract] [Full Text] [Related]
50. Immune tolerance induction with high von Willebrand factor/factor VIII content ratio concentrate in children with haemophilia A and high-responding inhibitor. Platokouki H; Pergantou H; Xafaki P; Komitopoulou A; Aronis S Haemophilia; 2009 Mar; 15(2):617-9. PubMed ID: 19175417 [No Abstract] [Full Text] [Related]
51. Platelet von Willebrand factor determination does not improve the diagnosis of patients with suspected Type 1 von Willebrand disease. Shihong I; Morris D; Konkle BA Haemophilia; 2009 Jan; 15(1):131-4. PubMed ID: 18976254 [TBL] [Abstract][Full Text] [Related]
52. von Willebrand disease, pregnancy and neuraxial anesthesia: a multi-disciplinary approach for successful regional anesthesia. Kailash F; Wilkerson D J Ark Med Soc; 2009 May; 105(11):259-60, 262. PubMed ID: 19475813 [TBL] [Abstract][Full Text] [Related]
53. von Willebrand factor: from figurant to main character in the scene of inflammation. Lenting PJ; Texier A; Casari C J Thromb Haemost; 2023 Apr; 21(4):710-713. PubMed ID: 36754680 [No Abstract] [Full Text] [Related]
58. Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma. Caudill JS; Nichols WL; Plumhoff EA; Schulte SL; Winters JL; Gastineau DA; Rodriguez V Transfusion; 2009 Apr; 49(4):765-70. PubMed ID: 19192257 [TBL] [Abstract][Full Text] [Related]
59. Summary of a workshop on potency and dosage of von Willebrand factor concentrates. Chang AC; Rick ME; Ross Pierce L; Weinstein MJ Haemophilia; 1998; 4 Suppl 3():1-6. PubMed ID: 10028311 [No Abstract] [Full Text] [Related]
60. Consideration of platelet function disorders in patients with reduced VWF levels. Millar CM; Riddell AF; Tuddenham EG Haemophilia; 2008 Sep; 14(5):1131-2. PubMed ID: 18665850 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]